Workflow guide · Catalyst discovery and verification
Monitor PDUFA, AdCom, and FDA updates
Connect the regulatory date with source-linked company news.
The situation
When this workflow becomes useful
A regulatory catalyst approaches and new FDA, company, or advisory-committee information may change timing, label expectations, or approval risk.
Best fit
Investors and traders whose research process is organized around clinical readouts, FDA decisions, conferences, and other discrete biotech events.
The challenge
Why the obvious approach breaks down
Connect the regulatory date with source-linked company news. The challenge is to preserve the source, define what changed, and connect the update to a decision instead of collecting disconnected information.
How to think about the task
The reasoning behind the workflow
A regulatory catalyst approaches and new FDA, company, or advisory-committee information may change timing, label expectations, or approval risk. For event-driven investors, the useful response is not simply to collect more links. The task is to decide what the new information changes, which source supports it, who needs to respond, and when the question should be reviewed again.
Connect the regulatory date with source-linked company news. The challenge is to preserve the source, define what changed, and connect the update to a decision instead of collecting disconnected information. A repeatable process keeps the work proportional to the decision and creates a record that another investor, analyst, editor, or team member can understand later.
Start with the decision this work must support
“Monitor PDUFA, AdCom, and FDA updates” becomes manageable when the user names the decision before opening more sources. The decision might be whether to escalate an event, update a thesis, change a calendar, commission deeper research, publish a story, or continue monitoring. A defined decision also makes it easier to exclude information that is interesting but not currently useful.
Build a source-linked change record
The core monitoring set for this workflow includes pdufa and adcom dates, review extensions, briefing documents and votes, company regulatory disclosures, label and post-marketing questions. Each material update should retain its source and previous known state. That makes timing changes, accumulating evidence, and repeated execution patterns visible instead of leaving the user with an isolated snapshot.
Turn monitoring into an owned output
A regulatory event file connecting the confirmed calendar, new disclosures, scenario implications, and the next source to monitor. The output should state what changed, what remains uncertain, who owns any follow-up, and which future event will resolve the question. The investor follows the full review process rather than treating the PDUFA date as an isolated binary entry.
Illustrative example
Illustrative workflow: monitor pdufa, adcom, and fda updates
Begin with the specific company, program, portfolio exposure, audience, or competitive set in scope. Review the highest-confidence source first, compare the disclosure with the previous record, and then use secondary context only where it helps explain the change.
Complete the workflow by producing the defined deliverable rather than ending with a collection of tabs. Assign any unresolved question to an owner and set the next review around the most relevant clinical, regulatory, financial, strategic, or editorial event.
Questions to answer before making a decision
- What has changed in pdufa and adcom dates, and why does it matter?
- What has changed in review extensions, and why does it matter?
- What has changed in briefing documents and votes, and why does it matter?
- What has changed in company regulatory disclosures, and why does it matter?
- What has changed in label and post-marketing questions, and why does it matter?
The workflow
A repeatable way to do the work
- 01
Define the specific decision or research question behind “monitor pdufa, adcom, and fda updates.”
- 02
Set the monitored scope around pdufa and adcom dates and review extensions.
- 03
Collect source-linked updates for briefing documents and votes and record what changed from the prior state.
- 04
Review company regulatory disclosures together with label and post-marketing questions before drawing a conclusion.
- 05
Produce the required output, assign follow-up ownership, and set the next review point.
Monitoring checklist
Signals to keep visible
Common mistakes
- Starting the monitoring process without a defined decision question
- Recording the latest state without preserving its source or previous state
- Ending with collected information but no owner, conclusion, or next review
Output and outcome
What good looks like
Deliverable
A regulatory event file connecting the confirmed calendar, new disclosures, scenario implications, and the next source to monitor.
Practical outcome
The investor follows the full review process rather than treating the PDUFA date as an isolated binary entry.
Where BioPharmSignal fits
Reduce the collection work around the decision.
Use LiveFeed and company pages for source-linked monitoring, the PDUFA Calendar for upcoming FDA milestones, and watchlists or alerts to keep the relevant tickers and keywords visible. The workflow still requires independent research and judgment.
Frequently asked questions
Who is this workflow for?
It is designed for event-driven biotech investors and adjacent biotech research users who need a repeatable, source-linked way to complete this task.
What should this workflow produce?
A regulatory event file connecting the confirmed calendar, new disclosures, scenario implications, and the next source to monitor.
What is the practical benefit?
The investor follows the full review process rather than treating the PDUFA date as an isolated binary entry.
Related workflows